Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 52(21): 6569-87, 2009 Nov 12.
Article in English | MEDLINE | ID: mdl-19845386

ABSTRACT

DHEA analogues with modifications at positions C3 or C17 were synthesized and evaluated for neuroprotective activity against the neural-crest-derived PC12 cell model of serum deprivation-induced apoptosis. The most potent compounds were the spiro-epoxy derivatives 17beta-spiro[5-androstene-17,2'-oxiran]-3beta-ol (20), (20S)-3beta,21-dihydroxy-17beta,20-epoxy-5-pregnene (23), and (20R)-3beta,21-dihydroxy-17alpha,20-epoxy-5-pregnene (27) with IC(50) values of 0.19 +/- 0.01, 99.0 +/- 4.6, and 6.4 +/- 0.3 nM, respectively. Analogues 20, 23, and 27, up to the micromolar range of concentrations, were unable to activate estrogen receptor alpha and beta (ERalpha and ERbeta) or to interfere with ER-dependent gene expression significantly. In addition, they were unable to stimulate the growth of Ishikawa, MCF-7, and LNCaP cells. Our results suggest that the spiro-epoxyneurosteroid derivatives 20, 23, and 27 may prove to be lead molecules for the synthesis of novel neuroprotective agents.


Subject(s)
Apoptosis/drug effects , Dehydroepiandrosterone/analogs & derivatives , Dehydroepiandrosterone/chemical synthesis , Neuroprotective Agents/chemical synthesis , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Dehydroepiandrosterone/adverse effects , Dehydroepiandrosterone/pharmacology , Estrogen Receptor alpha/agonists , Estrogen Receptor alpha/biosynthesis , Estrogen Receptor beta/agonists , Estrogen Receptor beta/biosynthesis , Humans , Models, Molecular , Molecular Conformation , Neurons/cytology , Neurons/drug effects , Neuroprotective Agents/adverse effects , Neuroprotective Agents/pharmacology , Rats , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...